TSLPR (CRLF2) Antibody, anti-human, REAfinity™
Synonyms: TSLP-R, TSLP Receptor, Thymic stromal lymphopoietin protein receptor, cytokine receptor-like 2, CRL2, IL-XR
RECOMBINANT EXTENDED VALIDATION
Clone:
REA1342 | 1B4
Type of antibody:
Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for TSLPR (CRLF2) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
PE
PE-Vio 770
Vio Bright V423
Vio Bright V600
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-133-831, 130-133-766
Description:
Mature moDCs were stained with TSLPR (CRLF2)antibodies or with the corresponding REA Control (S) antibodies (left image), as well as with CD11c antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
Extended validation for TSLPR (CRLF2) Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1342
1B4
high
Ebio1A6(1A6)
high
1F11/TSLPR
low

Cells were incubated with an excess of purified unconjugated TSLPR (CRLF2) (REA1342) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for TSLPR (CRLF2). Monocyte derived dendritic cells (MODCs) were stained with TSLPR (CRLF2) antibodies and with a suitable counterstaining. As a control, TSLPR (CRLF2)antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using TSLPR (CRLF2) (REA1342). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for TSLPR (CRLF2) Antibody, anti-human, REAfinity™
Overview

Clone REA1342 recognizes the human TSLPR antigen, also known as CRLF2 or IL-XR. TSLPR is a type I membrane receptor that forms a heterodimeric complex with IL-7R to bind with TSLP, that activates JAK2, STAT3, and STAT5 pathways to stimulate cell proliferation. TSLP-R is primarily expressed in myeloid cells, dendritic cells, monocytes, and weakly expressed in T cells. Expression is also found in heart, skeletal muscle, kidney and liver.

REA1342 displays negligible binding to Fc receptors.

Alternative names

TSLP-R, TSLP Receptor, Thymic stromal lymphopoietin protein receptor, cytokine receptor-like 2, CRL2, IL-XR

Detailed product information

Technical specifications

Clone
REA1342
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Recombinant antibodies
Species reactivity
human
Antigen
TSLPR (CRLF2)
Molecular mass of antigen [kDa]
39,7
Distribution of antigen
myeloid cells, dendritic cells, monocytes, T cells, heart, liver, kidney, skeletal muscle
Entrez Gene ID

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for TSLPR (CRLF2) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for TSLPR (CRLF2) Antibody, anti-human, REAfinity™
Publications
  1. Zhang, W. et al. (2001) Identification of a novel type I cytokine receptor CRL2 preferentially expressed by human dendritic cells and activated monocytes. Biochem. Biophys. Res. Commun. 281 (4): 878-883
  2. Rochman, I. et al. (2007) Cutting edge: direct action of thymic stromal lymphopoietin on activated human CD4+ T cells. J Immunol 178 (11): 6720-6724
  3. Roll, J. D. et al. (2010) CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res. 70 (19): 7347-7352

You have previously chosen International as your location.
What do you want to do?